Precision Neuroscience IPO

Precision Neuroscience is developing minimally invasive brain-computer interface technology through their Layer 7 Cortical Interface, a thin-film electrode array that can be placed on the surface of the brain without penetrating brain tissue. Founded by former Neuralink co-founder Benjamin Rapoport, the company aims to create BCIs that require less invasive surgical procedures while still providing high-resolution neural signal recording. Their approach focuses on helping patients with paralysis, depression, and other neurological conditions by enabling direct communication between the brain and external devices.

The company's technology differentiates itself from competitors by emphasizing safety and reversibility, using electrodes that sit on the brain's surface rather than penetrating deep into neural tissue. This approach potentially reduces surgical risks and complications while still enabling therapeutic applications. Precision Neuroscience has been conducting early feasibility studies and working toward clinical trials, positioning themselves in the rapidly evolving brain-computer interface market that has attracted significant attention from both medical communities and technology investors.